These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36776661)

  • 1. Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States.
    Smith JT; Velayos FS; Niu F; Liu V; Delate T; Pola S; Le K; Hui RL
    Crohns Colitis 360; 2021 Jul; 3(3):otab051. PubMed ID: 36776661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.
    Ho SL; Niu F; Pola S; Velayos FS; Ning X; Hui RL
    BioDrugs; 2020 Jun; 34(3):395-404. PubMed ID: 32103457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
    Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
    Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
    Baker JF; Bakewell C; Dikranian A; Lam G; O'Brien J; Moore PC; Yu M; Hur P; Masri KR
    Rheumatol Ther; 2024 Jun; 11(3):841-853. PubMed ID: 38507187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration.
    Patel S; Walsh J; Pinnell D; Pei S; Chen W; Rojas J; Rathod A; Johnson J; Gawron A; Curtis JR; Baker JF; Cannon GW; Wu D; Lai M; Sauer BC
    Medicine (Baltimore); 2024 Sep; 103(37):e39476. PubMed ID: 39287304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P013 Resolution of Infliximab Associated Infusion Hypersensitivity After Switching to Biosimilar Infliximab-dyyb.
    Irani M; Bryant R; Lofton H; Abraham B
    Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S3. PubMed ID: 37461933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Rapid Infliximab Biosimilar Infusions in Patients With Inflammatory Bowel Disease.
    Kim JY; Bhat S
    Ann Pharmacother; 2022 Mar; 56(3):280-284. PubMed ID: 34192881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.
    Ho SL; Niu F; Pola S; Velayos FS; Ning X; Hui RL
    BioDrugs; 2020 Jun; 34(3):405. PubMed ID: 32253718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Biosimilar Infliximab-Dyyb in Non-Infectious Uveitis.
    Zaguia F; Randerson EL; Moorthy RS; Goldstein DA
    Ocul Immunol Inflamm; 2024 Oct; 32(8):1517-1521. PubMed ID: 37582248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Perspectives on Switching from Infliximab to Infliximab-dyyb in Patients with Rheumatologic Diseases in the United States.
    Chau J; Delate T; Ota T; Bhardwaja B
    ACR Open Rheumatol; 2019 Mar; 1(1):52-57. PubMed ID: 31777780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence Study.
    Meyer A; Rudant J; Drouin J; Weill A; Carbonnel F; Coste J
    Ann Intern Med; 2019 Jan; 170(2):99-107. PubMed ID: 30534946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
    Blair HA; Deeks ED
    BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn's disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain.
    Martínez-Lozano H; Miranda-Bautista J; González-Lama Y; Carpio D; Barreiro-de Acosta M; Pérez-Calle JL; Relea Pérez L; Villa K; Matallana V; Calvo M; Vera MI; Pérez Galindo P; Mora-Cuadrado N; López-Serrano P; Marín-Jiménez I; Menchén L
    Rev Esp Enferm Dig; 2021 Mar; 113(3):170-178. PubMed ID: 33213166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world data on the infliximab biosimilar CT-P13 (Remsima
    Huguet JM; Cortés X; Bosca-Watts MM; Aguas M; Maroto N; Martí L; Amorós C; Paredes JM
    World J Clin Cases; 2021 Dec; 9(36):11285-11299. PubMed ID: 35071559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.
    Dutcher SK; Fazio-Eynullayeva E; Eworuke E; Carruth A; Dee EC; Blum MD; Nguyen MD; Toh S; Panozzo CA; Lyons JG
    Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):786-795. PubMed ID: 31828887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.
    Dean EB; Johnson P; Bond AM
    JAMA Netw Open; 2021 Jan; 4(1):e2034776. PubMed ID: 33502485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis.
    Meyer A; Rudant J; Drouin J; Coste J; Carbonnel F; Weill A
    Aliment Pharmacol Ther; 2019 Aug; 50(3):269-277. PubMed ID: 31115919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab.
    Lin I; Melsheimer R; Bhak RH; Lefebvre P; DerSarkissian M; Emond B; Lax A; Nguyen C; Wu M; Young-Xu Y
    Curr Med Res Opin; 2022 Apr; 38(4):613-627. PubMed ID: 35125053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab Biosimilar CT-P13 Observational Studies for Rheumatoid Arthritis, Inflammatory Bowel Diseases, and Ankylosing Spondylitis: Pooled Analysis of Long-Term Safety and Effectiveness.
    Cheon JH; Nah S; Kang HW; Lim YJ; Lee SH; Lee SJ; Kim SH; Jung NH; Park JE; Lee YJ; Jeon DB; Lee YM; Kim JM; Park SH
    Adv Ther; 2021 Aug; 38(8):4366-4387. PubMed ID: 34250583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.